Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced that FDA granted approval of Simtriyo (centanafadine), a once-daily extended-release capsule for the treatment of attention-deficit hyperactivity disorder in adults and pediatric patients aged 6 years and older weighing at least 20kg. Today's approval reflects our commitment to advancing innovative treatment options that address the diverse needs of patients and families managing ADHD. Dr. Lenard A. Adler, director of the adult ADHD program at NYU Langone Health, pointed to the persistent burden many patients face even under existing treatment. "Even when on treatment, because of the heterogenic nature of ADHD, many patients continue to experience symptoms that can interfere with daily functioning. The approval of Simtriyo introduces a novel mechanism of action and expands the range of options available to healthcare professionals and patients.